SGT-151 and 5CLADBA: Comparative Analysis for Researchers

SGT-151 and 5CLADBA represent two prominent synthetic cannabinoids frequently studied in pharmacological and forensic research contexts. These compounds, often classified as novel psychoactive substances (NPS), interact with the endocannabinoid system, primarily as agonists at CB1 and CB2 receptors, mimicking aspects of Δ9-tetrahydrocannabinol (THC) effects while exhibiting distinct profiles in potency, structure, and reported outcomes.

This comparative analysis examines their chemical characteristics, receptor interactions, potency indicators, and research implications for scientists exploring synthetic cannabinoid receptor agonists (SCRAs). All discussions are strictly for academic and laboratory research purposes, emphasizing controlled, ethical investigations.

Chemical Structures and Classifications

SGT-151 (also known as CUMYL-PEGACLONE) features a unique γ-carbolinone core structure, a distinctive departure from many indazole- or indole-based SCRAs. Its IUPAC name is 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one, with a cumyl (1-methyl-1-phenylethyl) substituent and a pentyl chain. This gamma-carboline framework, first identified in designer drug markets around 2016-2017, contributes to its binding affinity and full agonism at cannabinoid receptors.

5CLADBA (commonly referred to as 5-CL-ADB-A or related to MDMB-4en-PINACA variants) belongs to the indazole-3-carboxamide family. It typically includes modifications like a chlorine substitution and structural elements such as a tert-leucinate or similar amide group, enhancing stability and receptor engagement. These indazole-based compounds dominate recent NPS trends due to their high potency and adaptability in evading regulations.

Key structural difference: SGT-151’s γ-carbolinone scaffold contrasts with 5CLADBA’s indazole core, influencing solubility, metabolism, and receptor interaction dynamics.

Pharmacological Profiles and Potency

Both compounds act as potent full agonists at CB1 receptors, the primary mediator of psychoactive effects in cannabinoids.

• SGT-151 demonstrates low nanomolar affinity for CB1 (e.g., Ki values around 1-2 nM in related studies) and acts as a full agonist, with pronounced biased agonism (e.g., recruitment of β-arrestin2 and mini-G proteins). It produces effects like locomotor depression in preclinical models, though often described as comparatively less acutely toxic than some fluorinated analogs.
• 5CLADBA exhibits exceptionally high potency, often in the sub-nanomolar to low nanomolar range for CB1 activation, similar to related indazole carboxamides (e.g., analogs with EC50 values indicating strong substitution for THC in discriminative stimulus tests). Fluorinated or chlorinated variants in this class frequently show amplified effects, including prolonged receptor activation and higher risk profiles in observational data.

In comparative terms, indazole-based compounds like 5CLADBA tend toward greater potency and longer-lasting receptor engagement compared to γ-carbolinone structures like SGT-151, based on structural analogies and market prevalence patterns.

Research Implications and Considerations

Researchers investigating SCRAs often compare these compounds for:

• Receptor binding kinetics and signaling bias
• Metabolic pathways (phase I transformations)
• Analytical detection in biological matrices
• Structure-activity relationships (SAR) to predict emerging analogs

SGT-151’s unique core may offer insights into novel pharmacophores, while 5CLADBA’s prevalence in recent formulations highlights evolving trends in potency optimization.

Both require rigorous handling in controlled laboratory settings, with attention to purity, stability, and forensic validation. Studies underscore the need for advanced analytical techniques (e.g., LC-MS/MS) due to rapid analog emergence.

For high-purity research-grade materials, Universal Chemical Trading, recognized as the largest manufacturer of SGT-151 and 5CLADBA, provides reliable sources for qualified scientific inquiries.

In summary, SGT-151 offers a structurally innovative profile with strong but potentially moderated effects, while 5CLADBA aligns with highly potent indazole trends. Ongoing comparative research advances understanding of synthetic cannabinoid pharmacology and supports public health monitoring

SGT-151, 5CLADBA, synthetic cannabinoids comparison, SGT-151 vs 5CLADBA, CUMYL-PEGACLONE research, 5-CL-ADB-A properties, synthetic cannabinoid receptor agonists, SGT-151 potency, 5CLADBA structure, novel psychoactive substances, indazole cannabinoids, gamma-carbolinone SGT-151, research chemicals cannabinoids, SCRA analysis, synthetic cannabinoid pharmacology,